~~<i id='2E7B759DEB'><strike id='2E7B759DEB'><tt id='2E7B759DEB'><pre id='2E7B759DEB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：hotspot 2025-09-29 01:34:53 - browse：2

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Amylyx's ALS drug launch starts strong. It could be trouble for FDA

hotspot

knowledge

hotspot

leisure time

explore

hotspot

Atumorinvasionintoaveininacaseofcolorectalcancer.WikimediaCommonsWhenboththenurseandthe doctorbroked

WSS

New Alzheimer's drugs heat up race for early detection blood tests

Biden warns of ‘dark winter’ during final presidental debate

Senate panel puts off hardest PBM reforms for another day

STAT Report: Patient voices and perspectives

How doctors’ personal politics affect patients

Maui's cultural, historic landmarks damaged in the devastating wildfires

hotspot

leisure time

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What to know about Virgin Galactic's 1st mission taking paying customers to space

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Will the FTC rein in IQVIA's health data empire?

Walensky prepares to leave CDC — and Congress — behind

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A new crop of companies is reshaping the health data economy

Bright Health sells Medicare Advantage business to Molina

Search called off for baby washed away in Pennsylvania flash flood

knowledge

Biogen says it will cut costs by $700 million, slash 1,000 jobs

New Alzheimer's drugs heat up race for early detection blood tests

Drastic changes should bring profitability, startup health insurers say

Dems pitch expanding Medicare power to negotiate drug prices

The haunting brain science of long Covid

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

hotspot

leisure time

explore

hotspot